Bausch Health Companies Inc. (TSE:BHC - Free Report) - Research analysts at Zacks Research raised their Q3 2024 earnings estimates for shares of Bausch Health Companies in a note issued to investors on Tuesday, October 22nd. Zacks Research analyst R. Department now anticipates that the company will earn $1.44 per share for the quarter, up from their prior estimate of $1.41. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q2 2025 earnings at $1.34 EPS, Q3 2026 earnings at $1.80 EPS and FY2026 earnings at $6.85 EPS.
A number of other brokerages have also recently weighed in on BHC. Evercore ISI raised Bausch Health Companies to a "hold" rating in a research note on Tuesday, October 15th. Raymond James raised shares of Bausch Health Companies to a "hold" rating in a research note on Wednesday, July 10th.
Get Our Latest Analysis on Bausch Health Companies
Bausch Health Companies Price Performance
BHC stock traded down C$0.03 on Wednesday, hitting C$11.18. 92,521 shares of the company's stock traded hands, compared to its average volume of 377,807. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of 7,583.76. The stock has a market cap of C$4.10 billion, a price-to-earnings ratio of -6.41, a P/E/G ratio of 0.21 and a beta of 0.77. Bausch Health Companies has a 1-year low of C$5.45 and a 1-year high of C$15.43. The stock has a fifty day moving average of C$9.43 and a 200-day moving average of C$9.96.
Bausch Health Companies (TSE:BHC - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported C$1.22 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of C$1.22. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The firm had revenue of C$3.29 billion for the quarter, compared to analyst estimates of C$3.20 billion.
Insider Buying and Selling
In other news, Senior Officer Seana Lynne Carson sold 13,370 shares of the company's stock in a transaction dated Friday, September 6th. The stock was sold at an average price of C$8.38, for a total value of C$112,087.40. Company insiders own 11.28% of the company's stock.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Featured Articles
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
